Does the Melanoma Vaccine Trial Apply to Older Adults?

On Aug. 19, 2026, Merck and Moderna announced that their Phase 3 INTerpath-001 trial had met two endpoints in people with completely resected stage IIB through IV melanoma: recurrence-free survival and distant metastasis-free survival. The trial tested intismeran autogene, a personalized mRNA cancer vaccine, together with pembrolizumab, better known by the brand name KEYTRUDA. The study enrolled 1,137 patients and randomized them 2:1 to receive the vaccine plus pembrolizumab or placebo plus pembrolizumab, and the endpoints were met at a pre-specified interim analysis.[1]

That is a real milestone: the companies described it as the first positive Phase 3 readout for a personalized mRNA cancer vaccine. But the public announcement is still topline. It does not provide the Phase 3 effect size, age-specific results, overall survival results, or a detailed side-effect breakdown by age. For an older adult reading the headline after melanoma surgery, the honest answer is: this news is promising, but it does not yet tell you how much benefit—or how much risk—applies to someone in their late 60s, 70s, or 80s.

One clarification matters right away: this is not a preventive vaccine for healthy people. It is an adjuvant treatment being studied after surgery for stage IIB through IV melanoma that has been completely resected. Intismeran is made for an individual patient’s tumor and is designed to target up to 34 neoantigens; in the Phase 3 trial, it was given at 1 mg every three weeks for up to nine doses, alongside pembrolizumab 400 mg by IV every six weeks for about one year.[1]

Why the older-adult question cannot be treated as a footnote

Melanoma is not only a young person’s skin cancer. SEER data put the median age at diagnosis at 67. The largest diagnosis share listed by age group is 27.8% among people ages 65 to 74. Deaths skew older still: the median age at death is 73, and the 75 to 84 group accounts for the largest listed share of deaths, at 26.7%.[2]

So when a melanoma treatment makes headlines, older adults are not a special-interest subgroup. They are central to the real-world question. A 52-year-old trial participant with few other health problems and a 79-year-old patient with kidney disease, arthritis medications, and a history of autoimmune symptoms may both be “melanoma patients,” but their risk calculations can look very different in the exam room.

Cancer trials have a long history of underrepresenting older patients. Sedrak and colleagues reported that adults 70 and older make up roughly 42% of the cancer population, but only about 24% of participants in FDA-registered trials and under 10% of participants in NCI-sponsored trials. They also describe barriers at the system, provider, patient, and caregiver levels that can keep older adults out of studies.[3]

A later analysis of National Clinical Trials Network studies from 2016 through 2021 found that people 70 and older remained under-enrolled, with the gap widening in the 75 to 79, 80 to 84, and 85-plus age groups. In melanoma and skin-cancer trials specifically, 66.0% of enrollees were under 65, compared with 44.7% of incident cases.[4]

That background does not prove INTerpath-001 under-enrolled older adults. The public topline release simply has not given the age distribution or age-subgroup results. But it does explain why older patients should not accept a broad headline as a personal answer.

What we know from earlier vaccine data—and what we do not

The excitement around INTerpath-001 did not come out of nowhere. NYU Langone reported five-year follow-up from an earlier Phase 2b study of the same vaccine approach with pembrolizumab in high-risk melanoma. In that Phase 2b context—not the new Phase 3 readout—the combination was associated with a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death. The reported hazard ratios were 0.51 and 0.411, respectively.[5]

The same Phase 2b follow-up reported that 68.8% of patients receiving the vaccine combination were cancer-free at five years, compared with 49.1% of those receiving pembrolizumab alone. Overall survival was reported as 92.2% versus 71.3%, and side effects described in that report included fatigue, injection-site pain, and chills.[5]

Those numbers help explain why oncologists and cancer researchers are paying attention. They should not be quietly pasted onto the Phase 3 headline. The Phase 3 trial has publicly reported that it met its recurrence-free survival and distant metastasis-free survival endpoints; it has not yet publicly reported the size of those benefits.

There is another trap worth avoiding. A search snippet or label table showing older-age percentages for KEYTRUDA does not automatically describe this melanoma vaccine trial. The public INTerpath-001 announcement does not provide a “44% ages 65 to 74” or “26% ages 75-plus” breakdown for the vaccine study, and those figures should not be treated as INTerpath-001 data.

Pembrolizumab risks still matter

For many older patients, the vaccine part of the headline is the new and unfamiliar piece. But pembrolizumab is not a casual background medication. It is an immune checkpoint inhibitor, and immune treatments can cause inflammation in organs that have nothing to do with the original melanoma.

Mayo Clinic’s pembrolizumab monograph says elderly patients are more likely to have serious unwanted effects, so caution may be needed in this age group.[6] That does not mean older adults should not receive pembrolizumab. Many do. It means the risk conversation should be specific: kidney function, autoimmune history, lung symptoms, bowel symptoms, diabetes risk, frailty, falls, and the medication list all matter.

A German retrospective study reported by CURE raised a cautionary signal in patients 75 and older receiving adjuvant checkpoint inhibitors for melanoma. In that report, the 75-plus group had more skin toxicity, colitis or diarrhea, and nephritis than younger patients; discontinuation was also reported more often in the older group, and median disease-free survival was shorter.[7]

That finding should be handled carefully. It was a small observational study, not a randomized answer for every older patient, and an interviewed expert disputed the strength of the conclusion on sample-size grounds.[7] Still, it is a useful reminder that “tolerable” in a study report is not the same as “easy” for a particular older adult living alone, recovering from surgery, or already managing several chronic conditions.

For families thinking through day-to-day monitoring, the practical issue is often not one dramatic side effect. It is the accumulation of fatigue, diarrhea, appetite changes, dizziness, weakness, confusion, or new pain between visits. We have a separate plain-language guide on cancer vaccine side effects and fall risk in older adults, and caregivers may also find it useful to keep a simple symptom log using the same habits described in how to monitor health changes in elderly parents.

What is still missing from the Phase 3 public record

The most important missing pieces for older adults are not obscure scientific details. They are the things a patient and family would reasonably want before changing expectations: the absolute benefit size, the age distribution, age-subgroup outcomes, treatment discontinuation by age, serious side effects by age, quality-of-life data, and overall survival follow-up.

Expert reactions collected after the topline announcement noted that the true Phase 3 benefit magnitude, subgroup analyses, quality-of-life findings, and overall survival results were not yet public, with fuller data expected at an upcoming international medical meeting.[8] CNN also reported that regulatory filings were expected within months.[9]

Regulatory review may move quickly, but approval status and personal suitability are separate questions. A treatment can be important for the field and still require a careful individual discussion for an 82-year-old with limited reserve. It can also be reasonable for an older patient to ask about it without being accused of chasing hype.

Five questions to bring to the oncology visit

This article is for education, not medical advice. The next step is not to decide from a headline; it is to bring sharper questions to the oncologist who knows the stage, pathology report, surgery status, scans, medications, and overall health picture.

1. Does my melanoma situation match the trial population? Ask whether the stage, surgical status, and “high-risk” features line up with INTerpath-001: completely resected stage IIB through IV melanoma after surgery.
2. Are age-subgroup data available yet? Ask whether the meeting abstract, presentation, or prescribing discussions include results for adults 65 and older, 75 and older, or patients with multiple chronic conditions.
3. How do pembrolizumab risks apply to me specifically? Bring up age, kidney function, autoimmune history, lung or bowel disease, diabetes risk, steroid use, blood thinners, and the full medication list.
4. What symptoms should we track between visits? Ask which changes should trigger a phone call: diarrhea, rash, shortness of breath, fever, severe fatigue, dizziness, confusion, falls, new weakness, appetite loss, or reduced urination.
5. Would waiting for full data or regulatory review change my care plan today? Ask what the current standard option is now, what decision points are time-sensitive, and whether more complete Phase 3 data could realistically arrive before a treatment choice has to be made.

References

1. Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma — Merck, Aug. 19, 2026
2. Cancer Stat Facts: Melanoma of the Skin — SEER
3. Older Adult Participation in Cancer Clinical Trials: A Systematic Review of Barriers and Interventions — CA: A Cancer Journal for Clinicians, 2021
4. Older Adult Enrollment in Cancer Clinical Trials: A Report From the National Cancer Institute Clinical Trials and Translational Research Advisory Committee — JNCI Monographs, 2022
5. Cancer Vaccine Sustains 49 Percent Melanoma Reduction After 5 Years — NYU Langone
6. Pembrolizumab (intravenous route) — Mayo Clinic
7. Researchers Urge Caution of Immunotherapy in Older Patients With Melanoma — CURE
8. Expert reaction to top-line results from the phase 3 INTerpath-001 trial looking at an mRNA vaccine, intismeran, in combination with pembrolizumab for patients with completely resected stage IIB-IV melanoma — Science Media Centre
9. Moderna and Merck say their mRNA melanoma vaccine succeeded in a late-stage trial — CNN, Aug. 19, 2026